The new brands were developed with the aim to position not only the uniqueness of each company but also the common family identity. To emphasise the family identity the three companies will all feature a new typeface, developed exclusively for the Novo Group, and use a common blue colour in the visual expression of their identities.
Novozymes A/S
The Enzyme Business, which is being spun off into a new company, will be named Novozymes, and its logo will be an image of a four-leaf clover. The name Novozymes is signalling the company's link to the Novo Group as well as to its core business, enzymes. The four-leaf clover illustrates good fortune and the uniqueness with which enzymes can make nature and technology work together.
The Enzyme Business, which is being spun off into a new company, will be named Novozymes, and its logo will be an image of a four-leaf clover. The name Novozymes is signalling the company's link to the Novo Group as well as to its core business, enzymes. The four-leaf clover illustrates good fortune and the uniqueness with which enzymes can make nature and technology work together.
Novo Nordisk A/S
The Health Care business will remain in the continuing company and will keep the name Novo Nordisk. The familiar logo of the Apis bull, a sacred animal from ancient Egypt symbolising the god of science and art, will continue to be the company logo, however revitalised and modernised graphically.
The Health Care business will remain in the continuing company and will keep the name Novo Nordisk. The familiar logo of the Apis bull, a sacred animal from ancient Egypt symbolising the god of science and art, will continue to be the company logo, however revitalised and modernised graphically.
Novo A/S
The holding company Novo A/S, which was established in September 1999, will simply have the word Novo in the new unique typeface as its graphic design, signalling the strong family link to the two business companies.
The holding company Novo A/S, which was established in September 1999, will simply have the word Novo in the new unique typeface as its graphic design, signalling the strong family link to the two business companies.
The new graphic designs for the three companies will be effective from the time of the demerger around the turn of the year 2000/2001.
Novo Nordisk A/S is the world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzymes. Headquartered in Denmark, Novo Nordisk employs approximately 15,000 people in 61 countries and markets its products in 179 countries. Its B shares are listed on the stock exchanges in Copenhagen, London and Zurich. Its ADSs are listed on the New York Stock Exchange under the symbol "NVO". A demerger of Novo Nordisk with the intention to spin off the Enzyme Business into a separately listed company is expected to take place around the turn of the year 2000/2001. For further company information, visit Novo Nordisk on the World Wide Web at http://www.novo.dk.
For further information please contact:
Communications & Design
Media:
Elin K Hansen
Phone (direct) : (+45) 4442 3450
Elin K Hansen
Phone (direct) : (+45) 4442 3450
Media in North America:
Susan Toth Jackson
Phone: (+1) 212-867-0123
Susan Toth Jackson
Phone: (+1) 212-867-0123
Investors:
Michael Steen-Knudsen
Phone (Direct): (+45) 4442 6048
Michael Steen-Knudsen
Phone (Direct): (+45) 4442 6048
Investors:
Carsten Bøss
Phone: (direct) (+45) 4442 6047
Carsten Bøss
Phone: (direct) (+45) 4442 6047
Investors in North America:
Peter Lundby Hansen
Phone: (+1) 212-878-9607
Peter Lundby Hansen
Phone: (+1) 212-878-9607